Contact Your Financial Adviser Money Making MC
21
February 2018
 |
Lupin
(The Total Investment & Insurance Solutions)
Pharma
major, Lupin Ltd, announced in its filing to BSE that it has
received final green signal for its Oseltamivir Phosphate for Oral Suspension
from the United States Food and Drug Administration (USFDA). The approval is to
market the generic version of Tamiflu for Oral Suspension, 6 mg/mL.
Lupin, significant player in the Cardiovascular, Diabetology, Asthma, etc, shall commence promoting the product shortly.
Lupin's Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL is indicated for i) treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and ii) treatment of influenza A and B in patients 1 year and older. Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL had annual sales of ~USD358mn in the US (IQVIA MAT October, 2017).
Lupin, significant player in the Cardiovascular, Diabetology, Asthma, etc, shall commence promoting the product shortly.
Lupin's Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL is indicated for i) treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and ii) treatment of influenza A and B in patients 1 year and older. Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL had annual sales of ~USD358mn in the US (IQVIA MAT October, 2017).
Lupin Ltd is currently trading at Rs813.05 down by
Rs2.75 or 0.34% from its previous closing of Rs815.80 on the BSE. The
stock is currently trading below its 200 DMA.The Total Investment & Insurance Solutions
No comments:
Post a Comment